Jupiter Wellness announced a decision to delay the second half of its head-to-head trial between JW-100 and Eucrisa until after its IND meeting with the FDA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on JUPW:
- Jupiter Wellness announces approval to dual list on Upstream
- Jupiter Wellness gives corporate update including launch of clinical trials
- Jupiter Wellness looking forward ‘to capitalizing on progress’
- Jupiter Wellness appoints Ardis as exclusive Florida market distributor
- Jupiter Wellness plans to spin off Caring Brands as digital securities dividend